Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

1.

Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.

LaMontagne DS, Mugisha E, Pan Y, Kumakech E, Ssemaganda A, Kemp TJ, Cover J, Pinto LA, Safaeian M.

Vaccine. 2014 Oct 29;32(47):6303-11. doi: 10.1016/j.vaccine.2014.08.071. Epub 2014 Sep 16.

PMID:
25218297
2.

Lessons learned from HPV vaccine delivery in low-resource settings and opportunities for HIV prevention, treatment, and care among adolescents.

Tsu VD, Cernuschi T, LaMontagne DS.

J Acquir Immune Defic Syndr. 2014 Jul 1;66 Suppl 2:S209-16. doi: 10.1097/QAI.0000000000000175. Review.

PMID:
24918597
3.

Qualitative study of the feasibility of HPV vaccine delivery to young adolescent girls in Vietnam: evidence from a government-implemented demonstration program.

LaMontagne DS, Nghi NQ, Nga le T, Janmohamed A, Huyen DT, Hien NT, Tsu VD.

BMC Public Health. 2014 Jun 5;14:556. doi: 10.1186/1471-2458-14-556.

4.

Operational assessments of Sayana® Press provision in Senegal and Uganda.

Cover J, Blanton E, Ndiaye D, Walugembe F, Lamontagne DS.

Contraception. 2014 May;89(5):374-8. doi: 10.1016/j.contraception.2014.01.005. Epub 2014 Jan 18.

PMID:
24565737
5.

Reply to Harper.

LaMontagne DS.

J Infect Dis. 2014 Jul 15;210(2):331-2. doi: 10.1093/infdis/jiu073. Epub 2014 Feb 5. No abstract available.

PMID:
24501213
6.

Extended Middle East and North Africa: summary recommendations for the prevention of human papillomavirus infections and related cancers including cervical cancer.

Seoud M, Vaccarella S, El-Kak F, Sancho-Garnier H, Jumaan AO, Kim JJ, Garland SM, Stern PL, LaMontagne DS, Albero G, Bosch FX.

Vaccine. 2013 Dec 30;31 Suppl 6:G78-9. doi: 10.1016/j.vaccine.2012.11.078. No abstract available.

PMID:
24331823
7.

Addressing questions about the HPV vaccine project in India.

Lamontagne DS, Sherris JD.

Lancet Oncol. 2013 Nov;14(12):e492. doi: 10.1016/S1470-2045(13)70476-5. No abstract available.

PMID:
24176568
8.

Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam.

Levin CE, Van Minh H, Odaga J, Rout SS, Ngoc DN, Menezes L, Araujo MA, LaMontagne DS.

Bull World Health Organ. 2013 Aug 1;91(8):585-92. doi: 10.2471/BLT.12.113837. Epub 2013 Jun 19.

9.

Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.

Lamontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM.

J Infect Dis. 2013 Oct 15;208(8):1325-34. doi: 10.1093/infdis/jit363. Epub 2013 Jul 30.

10.

Influences on parental acceptance of HPV vaccination in demonstration projects in Uganda and Vietnam.

Galagan SR, Paul P, Menezes L, LaMontagne DS.

Vaccine. 2013 Jun 26;31(30):3072-8. doi: 10.1016/j.vaccine.2013.04.056. Epub 2013 May 15.

PMID:
23684835
11.
12.

Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries.

Steben M, Jeronimo J, Wittet S, Lamontagne DS, Ogilvie G, Jensen C, Smith J, Franceschi S.

Vaccine. 2012 Nov 20;30 Suppl 5:F183-91. doi: 10.1016/j.vaccine.2012.06.031. Review.

PMID:
23199962
13.

Parental acceptance of HPV vaccine in Peru: a decision framework.

Bartolini RM, Winkler JL, Penny ME, LaMontagne DS.

PLoS One. 2012;7(10):e48017. doi: 10.1371/journal.pone.0048017. Epub 2012 Oct 29.

14.

Knowledge of cervical cancer and HPV vaccine post- vaccination among mothers and daughters in Vietnam.

Paul P, LaMontagne DS, Le NT.

Asian Pac J Cancer Prev. 2012;13(6):2587-92.

15.

Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination.

Cover JK, Nghi NQ, LaMontagne DS, Huyen DT, Hien NT, Nga le T.

BMC Public Health. 2012 Aug 9;12:629. doi: 10.1186/1471-2458-12-629.

16.

Human papillomavirus vaccine inaccuracies.

Tsu VD, LaMontagne DS.

Am J Public Health. 2012 Mar;102(3):389-90; author reply 390. doi: 10.2105/AJPH.2011.300474. Epub 2012 Jan 19. No abstract available.

17.

Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries.

LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, Janmohamed A, Kumakech E, Mosqueira NR, Nguyen NQ, Paul P, Tang Y, Minh TH, Uttekar BP, Jumaan AO.

Bull World Health Organ. 2011 Nov 1;89(11):821-830B. doi: 10.2471/BLT.11.089862. Epub 2011 Sep 1.

18.

Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru.

Penny M, Bartolini R, Mosqueira NR, LaMontagne DS, Mendoza MA, Ramos I, Winkler JL, Villafana J, Janmohamed A, Jumaan AO.

Vaccine. 2011 Jul 12;29(31):5022-30. doi: 10.1016/j.vaccine.2011.04.078. Epub 2011 May 24.

PMID:
21609748
19.

Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.

Neuzil KM, Canh do G, Thiem VD, Janmohamed A, Huong VM, Tang Y, Diep NT, Tsu V, LaMontagne DS.

JAMA. 2011 Apr 13;305(14):1424-31. doi: 10.1001/jama.2011.407.

PMID:
21486975
20.

Human papillomavirus vaccine introduction in Vietnam: formative research findings.

Nghi NQ, Lamontagne DS, Bingham A, Rafiq M, Mai le TP, Lien NT, Khanh NC, Hong DT, Huyen DT, Tho NT, Hien NT.

Sex Health. 2010 Sep;7(3):262-70. doi: 10.1071/SH09123.

PMID:
20719213
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk